Join us LIVE on October 20 at 4:15 PM ET! Anixa CEO Dr. Amit Kumar will discuss recent progress in our ovarian cancer CAR-T and breast cancer vaccine programs, upcoming clinical milestones, and answer investor questions. 🎙️ Hosted by RedChip Register FREE: redchip.com/webinar/ANIX/833… #ANIX #Biotech

Could a vaccine one day prevent breast cancer? KATV 7 features Anixa CEO Dr. Amit Kumar discussing our investigational breast cancer vaccine, its completed Phase 1 trial, and the potential to train the immune system to fight cancer. Watch: katv.com/community/little-ro… #ANIX #BreastCancer

A first for our ovarian cancer CAR-T clinical trial. Anixa has reported the first case of stable disease at 90 days following treatment with lira-cel. The patient received the highest dose evaluated to date following lymphodepletion, and no dose-limiting toxicities have been observed in the trial to date. Multiple patients have also survived more than one year following treatment, including one beyond two years. Encouraging progress as we continue evaluating lira-cel in recurrent ovarian cancer. Read the announcement here: prnewswire.com/news-releases… #AnixaBiosciences #ANIX #OvarianCancer #CART

Breast Cancer Awareness Month in Times Square. 🎀 Nasdaq is recognizing Anixa Biosciences and our investigational breast cancer vaccine on the Nasdaq Tower. As we work to advance the vaccine into Phase 2, our vision extends beyond treating breast cancer—toward preventing recurrence and, ultimately, preventing the disease before it develops. #BreastCancerAwarenessMonth #AnixaBiosciences #ANIX #CancerVaccines #BreastCancer

More attention on Anixa’s investigational breast cancer vaccine and its potential to change how we approach this disease—from treatment and preventing recurrence to, ultimately, prevention. Thank you @KRCG13 for highlighting this important research. #AnixaBiosciences #ANIX #BreastCancer #CancerVaccines

🎥 Two cancer programs. Real clinical data. No debt. A new RedChip company overview highlights Anixa Biosciences (Nasdaq: ANIX), including our breast cancer vaccine, ovarian cancer CAR-T therapy, and capital-efficient business model. ▶️ Watch: youtube.com/watch?v=ixmcAfES… #ANIX #Biotech #CancerResearch

Could a vaccine one day help prevent triple-negative breast cancer before it develops? In a new Med Journal 360 interview, Anixa Biosciences discusses the science behind our investigational breast cancer vaccine and the strategy of targeting a protein associated with breast cancer to train the immune system to respond. It’s a fundamentally different vision for fighting cancer: prevention, not just treatment. ▶️ Watch the Med Journal 360 interview: medjournal360.com/breast-can… #AnixaBiosciences #ANIX #BreastCancer #CancerVaccines #CancerPrevention

🎥 Now available to watch Ahead of the H.C. Wainwright 28th Annual Global Investment Conference, hear Anixa Chairman & CEO Dr. Amit Kumar discuss the progress of our two clinical-stage oncology programs: • Breast cancer vaccine advancing toward Phase 2 • lira-cel CAR-T therapy for ovarian cancer Anixa will participate in the conference September 14–16 in NYC. ▶️ Watch Anixa’s presentation: journey.ct.events/view/95700… #AnixaBiosciences #ANIX #Biotech #CancerVaccines #CART #Oncology

What does participating in a clinical trial for a breast cancer vaccine actually look like? In a new RedChip Small Stocks, Big Money interview, Anixa CEO Dr. Amit Kumar discusses the science and vision behind our breast cancer vaccine—joined by Phase 1 trial patient Sherie, who shares her personal experience. From treating breast cancer today to the long-term goal of preventing it altogether, hear where we believe this program could ultimately lead. ▶️ Watch the interview here: youtube.com/watch?v=jCUvJY2b… #AnixaBiosciences #ANIX #BreastCancer #CancerVaccines #Immunotherapy

🎙️ Can we develop a vaccine to prevent breast cancer? Anixa Chairman & CEO Dr. Amit Kumar joins ChalkTalkJim to discuss the science behind our investigational breast cancer vaccine—and the vision of moving cancer vaccines from treatment toward true prevention. The conversation covers the vaccine’s novel target, Phase 1 safety and immune-response data, and what it will take to advance this approach. 🎧 Listen: buzzsprout.com/2161473/episo… #AnixaBiosciences #BreastCancer #CancerVaccines #Immunotherapy #ANIX

Anixa Biosciences will be at the 2026 Cantor Global Healthcare Conference on September 11. With two clinical-stage oncology programs advancing, we welcome the opportunity to share the Anixa story with healthcare-focused investors. 📍 Waldorf Astoria New York #AnixaBiosciences #ANIX #Biotech #Oncology #CancerResearch

📢 Anixa Biosciences is pleased to participate in the Nasdaq & LD Micro Inaugural SF Summit on September 9 at Nasdaq’s San Francisco headquarters. We look forward to sharing updates on our clinical programs and connecting with the investment community. #AnixaBiosciences #ANIX #Biotech #Oncology #Immunotherapy #Nasdaq

Anixa Biosciences is proud to join @Nasdaq in recognizing Ovarian Cancer Awareness Month in Times Square today. As we advance our novel CAR-T therapy for ovarian cancer, we remain focused on developing new treatment options for patients facing this challenging disease. #OvarianCancerAwarenessMonth #OvarianCancer #CART #CancerResearch #AnixaBiosciences #ANIX

Cancer vaccines are gaining momentum—and Anixa Biosciences is part of the story. A new CWON Press article examining the Moderna/Merck Phase 3 melanoma results highlights Anixa’s investigational breast cancer vaccine as another example of the expanding cancer vaccine landscape. The article notes our vaccine’s differentiated approach, the 74% protocol-defined immune response rate in Phase 1, and preparations for Phase 2. 📰 Read more: cwonpress.com/2026/08/26/mrn… #AnixaBiosciences #CancerVaccines #BreastCancer #Immunotherapy #Biotech #ANIX

Cancer vaccines continue to gain momentum. Merck & Moderna's positive Phase 3 results add further validation to the broader cancer vaccine field, including vaccine + checkpoint inhibitor combinations. $ANIX has already evaluated its #breastcancer vaccine with Keytruda® in Phase 1, generating antigen-specific T-cell responses with no major additional side effects. Encouraging progress for the field. #CancerVaccines #Oncology #Merck #Moderna

📰 New industry coverage from Outsourced Pharma The article highlights why Anixa Biosciences' investigational breast cancer vaccine represents more than another clinical program—it reflects a bold vision for the future of cancer prevention and immunotherapy. Read the article: outsourcedpharma.com/doc/a-v… #AnixaBiosciences #Biotech #Immunotherapy #BreastCancer #CancerResearch #ANIX

Patient who received breast cancer vaccine as part of clinical trial speaks about experience wptv.com/news/treasure-coast…

🎥 #ICYMI: Anixa Biosciences CEO Dr. Amit Kumar appeared on the RedChip Small Stocks, Big Money show on Bloomberg TV. Discussion highlights: ✔️ Breast cancer vaccine Phase 1 data (immune responses in 74% of participants) ✔️ Progress toward Phase 2 ✔️ Ovarian cancer CAR-T program updates ▶️ Watch the interview: youtube.com/watch?v=92m_0LXz… #AnixaBiosciences #Biotech #Immunotherapy #CancerResearch #ANIX

We appreciate the continued coverage from Water Tower Research. At Anixa Biosciences, we are advancing differentiated immunotherapy programs, including our therapeutic and preventative breast cancer vaccine and lira-cel, our CAR-T therapy for ovarian cancer. #AnixaBiosciences #Biotech #Immunotherapy #Oncology #CancerResearch #ANIX

We’re proud to collaborate with Moffitt Cancer Center on advancing innovative immunotherapy approaches. Our joint work on CAR-T technology for ovarian cancer reflects a shared commitment to developing differentiated solutions for patients with significant unmet needs. Appreciate the continued leadership and partnership. #AnixaBiosciences #MoffittCancerCenter #Biotech #Immunotherapy #CancerResearch